Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Porfimer sodium
Drug ID BADD_D01803
Description The purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of photodynamic therapy in the United States.
Indications and Usage Indicated in the treatment of esophageal cancer.
Marketing Status approved; investigational
ATC Code L01XD01
DrugBank ID DB00707
KEGG ID D03327
MeSH ID D017323
PubChem ID 135577896
TTD Drug ID D02JDL
NDC Product Code 76128-155
UNII Y3834SIK5F
Synonyms Dihematoporphyrin Ether | Ether, Dihematoporphyrin | Dihematoporphyrin Ester | Porfimer | DHP Ether | Porfimer Sodium | Photofrin | Photofrin II
Chemical Information
Molecular Formula C68H74N8O11
CAS Registry Number 87806-31-3
SMILES CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)O)C)C(=C4C)C(C)OC(C)C6=C(C7=CC 8=C(C(=C(N8)C=C9C(=C(C(=N9)C=C1C(=C(C(=N1)C=C6N7)C)CCC(=O)O)CCC(=O)O)C)C)C(C)O)C )C(=C3CCC(=O)O)C)CCC(=O)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Chapped lips07.05.01.004--Not Available
Oesophagitis ulcerative07.04.05.003--Not Available
Tumour haemorrhage24.07.01.028; 16.32.03.008--
Musculoskeletal chest pain22.09.01.001; 15.03.04.012--
Deep vein thrombosis24.01.02.003--Not Available
Post procedural haemorrhage12.02.05.004; 24.07.01.014--
Fluid imbalance14.05.01.003--Not Available
Bronchial ulceration22.03.02.010--Not Available
Eye oedema06.08.03.013--Not Available
Respiratory tract congestion22.02.07.003--Not Available
Lymphatic disorder01.09.01.003--Not Available
Nodule08.03.05.002--Not Available
Haemorrhage24.07.01.002--Not Available
Temperature intolerance08.01.09.022--Not Available
Post procedural complication12.02.05.018--Not Available
Angiopathy24.03.02.007--Not Available
Hot flush21.02.02.001; 08.01.03.027; 24.03.01.005--
Benign neoplasm16.02.02.007--Not Available
Breast disorder21.05.04.004--Not Available
Cardiac disorder02.11.01.003--Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Embolism24.01.01.009--
Infestation11.09.01.001; 23.11.01.002--Not Available
Malnutrition14.03.02.004--Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Oesophageal disorder07.11.02.001--Not Available
Porphyrin metabolism disorder03.08.01.006; 14.14.01.006; 09.01.10.004--Not Available
Decreased appetite08.01.09.028; 14.03.01.005--
Ill-defined disorder08.01.03.049--Not Available
The 7th Page    First    Pre   7 8    Next   Last    Total 8 Pages